10-Q: EBR Systems Reports Q3 2024 Financial Results, Cites Progress on WiSE CRT System

Sentiment:

Quarterly Report 12 November 2024 4:39 PM

EBR Systems, a medical device company, announced its Q3 2024 financial results, highlighting ongoing development of its WiSE CRT System and a recent capital raise.

Delay expectedThe company did not receive FDA approval by June 30, 2024, and therefore did not meet the draw requirements of the third and final tranche.

Capital raiseThe company completed a fully underwritten institutional placement and the institutional component of a 1-for-20 pro-rata accelerated non-renounceable entitlement issuance of 55,856,325 CDIs representing the same number of common stock at $ 0.82 Australian dollars per share, for proceeds of $ 29,483,822 , net of $ 1,776,170 of related issuance costs.In September 2024, the Company announced the retail component of the fully underwritten 1-for-20 pro-rata non-renounceable entitlement offer of 5,075,733 CDIs representing the same number of common stock at $ 0.82 Australian dollars per share.On October 16, 2024, the Company issued 5,075,733 CDIs and received proceeds of $ 2,595,864 , net of $ 165,694 of related issuance costs.

Worse than expectedThe company's net loss increased for both the three and nine months ended September 30, 2024, compared to the same periods in 2023.

Summary

EBR Systems reported a net loss of $10.1 million for the three months ended September 30, 2024, compared to a net loss of $9.1 million for the same period in 2023.
The company's research and development expenses decreased slightly, while general and administrative expenses increased significantly.
For the nine months ended September 30, 2024, the net loss was $30.7 million, compared to $24.7 million for the same period in 2023.
The company completed a capital raise in September 2024, issuing shares for net proceeds of approximately $29.5 million.
EBR Systems is focused on obtaining FDA approval for its WiSE CRT System and plans to begin commercialization upon approval.
As of September 30, 2024, EBR Systems had $74.2 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is still incurring losses, they have successfully raised capital and are progressing towards potential commercialization of their product.

Positives

EBR Systems successfully raised approximately $29.5 million in net proceeds through a share placement in September 2024.
The company's cash, cash equivalents, and marketable securities totaled $74.2 million as of September 30, 2024.
The company has submitted all required modules of its modular pre-market approval (PMA) to the Food and Drug Administration (FDA) and will plan to begin commercialization upon final FDA approval.

Negatives

EBR Systems continues to incur significant net losses, with a $10.1 million loss in Q3 2024 and a $30.7 million loss for the nine months ended September 30, 2024.
General and administrative expenses increased significantly, rising by 56.6% in Q3 2024.
The company did not receive FDA approval by June 30, 2024, and therefore did not meet the draw requirements of the third and final tranche.

Risks

The company's business strategy depends on the successful and timely FDA approval of its WiSE CRT System.
Market acceptance of the WiSE CRT System is crucial for the company's growth.
The company faces intense competition from larger, well-capitalized companies.
Reimbursement levels from third-party payors could impact the prices the company can charge for its products.
The company's future success depends on the cost, timing and results of its clinical trials and regulatory reviews.

Future Outlook

EBR Systems plans to begin commercialization of the WiSE CRT System upon final FDA approval and intends to commercialize the device in Australia and certain European countries following the U.S. launch.

Industry Context

The document does not provide enough information to assess the announcement's relation to broader industry trends or competitors.

Related Party Transactions

On September 25, 2024, Host-Plus, a beneficial owner of more than 5% of the company's common stock, participated in the institutional placement and purchased 7,868,138 CDIs for the aggregate purchase price of $ 4,403,403.

Stakeholder Impact

Shareholders: Dilution from recent equity offerings, potential for future value creation upon successful commercialization.
Employees: Continued employment and potential for growth within the company.
Customers: Potential access to a new cardiac pacing system upon regulatory approval.
Suppliers: Continued business relationship with the company.

Next Steps

The company plans to begin commercialization of the WiSE CRT System upon final FDA approval.
EBR Systems intends to commercialize the device in Australia and certain European countries following the U.S. launch and upon obtaining local regulatory approvals and securing reimbursement coverage.

Key Dates

Date	Description
2013	The Company and its stockholders adopted an equity incentive plan (the 2013 Plan)
2015-07-31	EBR Systems (UK) Limited (EBR-UK), was incorporated.
2017-02-23	EBR Systems (AUST) Pty Ltd (EBR-AU), was incorporated.
2021-05	The Company entered into an equipment purchase agreement for the purchase of certain software totaling $ 128,974.
2021-10-14	The Company replaced the 2013 Plan with the 2021 Plan, as the 2013 Plan was expiring.
2021-11-24	The Company completed its initial public offering of CDIs (CHESS Depositary Interests) and began trading on the Australian Securities Exchange (ASX) under the symbol EBR.
2022-06-30	The Company entered into a loan and security agreement with Runway Growth Finance Corp.
2022-07	The Company completed interim enrollment in the pivotal SOLVE-CRT study.
2023-06	The Company received the second tranche of $ 20,000,000 from Runway Growth Finance Corp.
2023-06	The Company completed an offering of 27,472,527 CDIs representing the same number of common stock at $ 0.91 Australian dollars per share, for proceeds of $ 15,604,896 , net of $ 895,314 of related issuance costs.
2023-07	The Company issued an additional 8,415,813 CDIs representing the same number of common stock at $ 0.91 Australian dollars per share, for proceeds of $ 5,010,231 , net of $ 104,634 of related issuance costs.
2024-01	The Company signed an addendum to the operating lease, extending the expiration of the lease through June 30, 2025, and adjusting the monthly rent from $ 35,606 per month to $ 50,000 per month.
2024-03	The Company signed an additional addendum to the operating lease, extending the expiration of the lease through December 31, 2025.
2024-03	The Company entered into an equipment purchase agreement for the purchase of software totaling $ 82,029.
2024-06-30	The draw period for the third tranche from Runway Growth Finance Corp ended.
2024-07	The Company signed an additional addendum to the operating lease, extending the expiration of the lease through December 31, 2026.
2024-09-25	The Company issued 55,856,325 shares of common stock at a price to the public of $ 0.56 per share in connection with an institutional placement and the institutional component of a 1-for-20 pro-rata accelerated non-renounceable entitlement offer on the ASX.
2024-10-16	The Company issued 5,075,733 CDIs and received proceeds of $ 2,595,864 , net of $ 165,694 of related issuance costs.
2027-06-15	The note payable from Runway Growth Finance Corp has a maturity date.

Keywords

WiSE CRT System, EBR Systems, Cardiac Resynchronization Therapy, FDA Approval, Financial Results, Medical Device, Capital Raise

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.